Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Arrowhead Pharmaceuticals Inc    ARWR

ARROWHEAD PHARMACEUTICALS INC (ARWR)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 01/18 04:00:00 pm
14.52 USD   -0.75%
2018ARROWHEAD PHARMACEUTICALS INC : annual earnings release
2018J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

ARROWHEAD PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/11/2019 | 05:24pm EST

Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain

Officers.

On January 7, 2019, Arrowhead Pharmaceuticals, Inc. (the "Company") and Peter Leone, the Company's Vice President of Strategic Business Initiatives, entered into a separation agreement (the "Agreement") providing for severance payments as set forth below.

Mr. Leone's position with the Company is eliminated and pursuant to the Agreement he shall receive an amount equal to three month's salary from the Company and the Company shall accelerate the vesting of any unvested stock options granted to Mr. Leone during his employment with the Company.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ARROWHEAD PHARMACEUTICALS
01/11ARROWHEAD PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (for..
AQ
2018ARROWHEAD PHARMACEUTICALS : Reports Inducement Grants under NASDAQ Marketplace R..
AQ
2018ARROWHEAD PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CO..
AQ
2018ARROWHEAD PHARMACEUTICALS, INC. : Results of Operations and Financial Condition,..
AQ
2018ARROWHEAD PHARMACEUTICALS INC : annual earnings release
2018ARROWHEAD PHARMACEUTICALS : Presents Late-Breaking Clinical Data on ARO-AAT at L..
AQ
2018ARROWHEAD PHARMACEUTICALS : Unveils Data From Two Studies
DJ
2018ARROWHEAD PHARMACEUTICALS : Files for Regulatory Clearance to Begin Phase 1 Stud..
AQ
2018ARROWHEAD PHARMACEUTICALS : Enters $3.7 Billion License and Collaboration Agreem..
AQ
2018JOHNSON & JOHNSON : Janssen Announces Exclusive, Worldwide License Agreement wit..
AQ
More news
Financials ($)
Sales 2019 190 M
EBIT 2019 99,7 M
Net income 2019 100 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 13,75
P/E ratio 2020
Capi. / Sales 2019 7,07x
Capi. / Sales 2020 29,0x
Capitalization 1 339 M
Chart ARROWHEAD PHARMACEUTICALS INC
Duration : Period :
Arrowhead Pharmaceuticals Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARROWHEAD PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 24,4 $
Spread / Average Target 68%
EPS Revisions
Managers
NameTitle
Christopher Richard Anzalone President, Chief Executive Officer & Director
Douglass B. Given Chairman
Bruce D. Given Chief Operating Officer
Kenneth Allen Myszkowski CFO & Principal Accounting Officer
James C. Hamilton Vice President & Head-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
ARROWHEAD PHARMACEUTICALS INC17.79%1 339
GILEAD SCIENCES10.60%89 493
VERTEX PHARMACEUTICALS14.97%49 757
REGENERON PHARMACEUTICALS11.75%44 532
GENMAB-4.59%9 536
NEUROCRINE BIOSCIENCES, INC.28.18%8 300